FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028860635> ?p ?o ?g. }

• W2028860635 endingPage "1115" @default.
• W2028860635 startingPage "1099" @default.
• W2028860635 abstract "Background: Because natural progesterone is poorly absorbed and rapidly metabolized, synthetic derivatives of progesterone, such as medroxyprogesterone acetate (MPA), are used in combination with estrogen in hormone replacement therapy. A micronized form of natural progesterone is available that is readily absorbed and reaches peak serum concentrations from 1 to 4 hours after administration. Objective: The purpose of this study was to compare the quality of life (QOL), menopausal symptoms, and costs associated with a natural micronized progesterone (MP) formulation versus MPA as add-on therapy to estrogen in hormone replacement for post-menopausal women. Methods: This prospective, multicenter, randomized, fixed-dose, open-label, parallel-group study enrolled postmenopausal, otherwise healthy, nonhysterectomized women 45 to 65 years of age who had been amenorrheic for ≥6 months and exhibited symptoms of estrogen deficiency. All women received 0.625 mg conjugated equine estrogens on days 1 to 25 of a 30-day cycle; on days 12 to 25, women were randomized to receive either MP 200 mg or MPA 5 mg; patients were followed for 9 months. QOL, the primary end point, was measured at baseline and months 3, 6, and 9 using the 36-Item Short-Form Health Survey (SF-36), the Nottingham Health Profile (NHP), and the condition-specific Women's Health Questionnaire (WHQ). Bleeding pattern, compliance, menopausal symptoms, and cost were evaluated as secondary end points. Costs (in 1997 Canadian dollars) were assessed from the societal perspective and included costs of study medication, hormone therapy monitoring, concomitant medication, outpatient resources, out-of-pocket expenses, and patient and caregiver time loss. Results: A total of 182 women were enrolled; 89 received MP and 93 received MPA. Improvements in climacteric symptoms were observed from baseline to month 9 for both treatments. Mean scores on all domains of the SF-36 at month 9 were greater than scores at baseline in both treatment groups but the increases were not statistically significant. All domains within the NHP and WHQ improved significantly over this period for both groups (P ≤ 0.008). Only patients receiving MP showed specific improvements in the menstrual problems and cognitive domains of the WHQ. The difference in average 9-month cost per patient was not statistically significant, at Can $367 ± $120 and Can $360 ± $369 for patients receiving MP and MPA, respectively. Conclusions: MP is a clinically effective, well-tolerated, and cost-comparable alternative to MPA." @default.
• W2028860635 created "2016-06-24" @default.
• W2028860635 creator A5080654312 @default.
• W2028860635 date "2001-07-01" @default.
• W2028860635 modified "2023-10-14" @default.
• W2028860635 title "Quality of life and costs associated with micronized progesterone and medroxyprogesterone acetate in hormone replacement therapy for nonhysterectomized, postmenopausal women" @default.
• W2028860635 cites W1493773294 @default.
• W2028860635 cites W1786860485 @default.
• W2028860635 cites W1965348990 @default.
• W2028860635 cites W1974743620 @default.
• W2028860635 cites W1980661472 @default.
• W2028860635 cites W2007824063 @default.
• W2028860635 cites W2011726234 @default.
• W2028860635 cites W2032244710 @default.
• W2028860635 cites W2080180078 @default.
• W2028860635 cites W2086126743 @default.
• W2028860635 cites W2120754250 @default.
• W2028860635 cites W2135902692 @default.
• W2028860635 cites W2150191771 @default.
• W2028860635 cites W2206109168 @default.
• W2028860635 cites W2314604683 @default.
• W2028860635 cites W2340750934 @default.
• W2028860635 cites W2408344781 @default.
• W2028860635 cites W2408346855 @default.
• W2028860635 cites W2465045692 @default.
• W2028860635 doi "https://doi.org/10.1016/s0149-2918(01)80094-1" @default.
• W2028860635 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11519773" @default.
• W2028860635 hasPublicationYear "2001" @default.
• W2028860635 type Work @default.
• W2028860635 sameAs 2028860635 @default.
• W2028860635 citedByCount "23" @default.
• W2028860635 countsByYear W20288606352013 @default.
• W2028860635 countsByYear W20288606352014 @default.
• W2028860635 countsByYear W20288606352015 @default.
• W2028860635 countsByYear W20288606352016 @default.
• W2028860635 countsByYear W20288606352017 @default.
• W2028860635 countsByYear W20288606352018 @default.
• W2028860635 countsByYear W20288606352020 @default.
• W2028860635 countsByYear W20288606352022 @default.
• W2028860635 crossrefType "journal-article" @default.
• W2028860635 hasAuthorship W2028860635A5080654312 @default.
• W2028860635 hasConcept C121608353 @default.
• W2028860635 hasConcept C126322002 @default.
• W2028860635 hasConcept C159110408 @default.
• W2028860635 hasConcept C168563851 @default.
• W2028860635 hasConcept C2775934596 @default.
• W2028860635 hasConcept C2776306185 @default.
• W2028860635 hasConcept C2777164284 @default.
• W2028860635 hasConcept C2778562196 @default.
• W2028860635 hasConcept C2779279991 @default.
• W2028860635 hasConcept C2779951463 @default.
• W2028860635 hasConcept C2780159708 @default.
• W2028860635 hasConcept C2780275930 @default.
• W2028860635 hasConcept C29456083 @default.
• W2028860635 hasConcept C530470458 @default.
• W2028860635 hasConcept C71924100 @default.
• W2028860635 hasConceptScore W2028860635C121608353 @default.
• W2028860635 hasConceptScore W2028860635C126322002 @default.
• W2028860635 hasConceptScore W2028860635C159110408 @default.
• W2028860635 hasConceptScore W2028860635C168563851 @default.
• W2028860635 hasConceptScore W2028860635C2775934596 @default.
• W2028860635 hasConceptScore W2028860635C2776306185 @default.
• W2028860635 hasConceptScore W2028860635C2777164284 @default.
• W2028860635 hasConceptScore W2028860635C2778562196 @default.
• W2028860635 hasConceptScore W2028860635C2779279991 @default.
• W2028860635 hasConceptScore W2028860635C2779951463 @default.
• W2028860635 hasConceptScore W2028860635C2780159708 @default.
• W2028860635 hasConceptScore W2028860635C2780275930 @default.
• W2028860635 hasConceptScore W2028860635C29456083 @default.
• W2028860635 hasConceptScore W2028860635C530470458 @default.
• W2028860635 hasConceptScore W2028860635C71924100 @default.
• W2028860635 hasIssue "7" @default.
• W2028860635 hasLocation W20288606351 @default.
• W2028860635 hasLocation W20288606352 @default.
• W2028860635 hasOpenAccess W2028860635 @default.
• W2028860635 hasPrimaryLocation W20288606351 @default.
• W2028860635 hasRelatedWork W1975559205 @default.
• W2028860635 hasRelatedWork W1984745009 @default.
• W2028860635 hasRelatedWork W2050149015 @default.
• W2028860635 hasRelatedWork W2071515900 @default.
• W2028860635 hasRelatedWork W2071929606 @default.
• W2028860635 hasRelatedWork W2183733289 @default.
• W2028860635 hasRelatedWork W2308403053 @default.
• W2028860635 hasRelatedWork W2419271003 @default.
• W2028860635 hasRelatedWork W4310946921 @default.
• W2028860635 hasRelatedWork W79115340 @default.
• W2028860635 hasVolume "23" @default.
• W2028860635 isParatext "false" @default.
• W2028860635 isRetracted "false" @default.
• W2028860635 magId "2028860635" @default.
• W2028860635 workType "article" @default.